Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
Fiction
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/8e/cb/85/8ecb8525-eca2-a6a0-0117-b9e8d7cbc604/mza_12025572446588826064.jpg/600x600bb.jpg
Business Of Biotech
Ben Comer
280 episodes
3 days ago
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. Mardi describes how drug companies transition from an R&D focus to commercializing products, how to read IPO windows and manage expectations, pricing new drugs, and balancing commer...
Show more...
Management
Business,
Science,
Life Sciences
RSS
All content for Business Of Biotech is the property of Ben Comer and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. Mardi describes how drug companies transition from an R&D focus to commercializing products, how to read IPO windows and manage expectations, pricing new drugs, and balancing commer...
Show more...
Management
Business,
Science,
Life Sciences
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/8e/cb/85/8ecb8525-eca2-a6a0-0117-b9e8d7cbc604/mza_12025572446588826064.jpg/600x600bb.jpg
The Business Case For Health Economics And Outcomes Research With ISPOR's Rob Abbott
Business Of Biotech
57 minutes
1 month ago
The Business Case For Health Economics And Outcomes Research With ISPOR's Rob Abbott
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and outcomes research (HEOR), and not just with patients and commercial payers. HEOR, viewed as a strategic lever as opposed to a compliance exercise, can help answer investor questions about market differentiation, pricing pathways, and real world p...
Business Of Biotech
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. Mardi describes how drug companies transition from an R&D focus to commercializing products, how to read IPO windows and manage expectations, pricing new drugs, and balancing commer...